| Methods |
Different doses used in devices.
Design: randomised, double‐blind, crossover study
Device: Turbuhaler
Drug: salbutamol
Dose: 200ug in TH; 100ug in pMDI, both treatments given qid for 2 weeks each.
Duration: 2 weeks |
| Participants |
37 adults (18 women), mean age 39 yrs, FEV1 72% predicted, and 15% or greater increase in FEV1 after 200ug salbutamol from pMDI. |
| Interventions |
Total study duration was 4 weeks; 1 week run‐in followed by 2 weeks treatment and 1 week of washout in between. |
| Outcomes |
PEFR, FEV1 (measured 15 minutes post‐dose), preference, beta‐2 use and symptoms. |
| Notes |
|
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
Information not available (Cochrane Grade B) |
